| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD6 |
| Uniprot No | P30203 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 308-400aa |
| 氨基酸序列 | CGTAVERPKGLPHSLSGRMYYSCNGEELTLSNCSWRFNNSNLCSQSLAAR VLCSASRSLHNLSTPEVPASVQTVTIESSVTVKIENKESRELM |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD6重组蛋白的3篇示例参考文献(注：文献为虚构示例，实际引用需核实真实来源)：
---
1. **文献名称**：*Structural characterization of the extracellular domain of human CD6 using X-ray crystallography*
**作者**：Llorian-Salvador, M., et al.
**摘要**：本研究通过X射线晶体学解析了人源CD6蛋白胞外结构域的高分辨率三维结构，揭示了其SRCR结构域的配体结合位点，为靶向CD6的免疫调节药物设计提供了结构基础。
2. **文献名称**：*Recombinant CD6 as a therapeutic target in autoimmune diseases: Preclinical evaluation in rheumatoid arthritis models*
**作者**：Esteban, G., et al.
**摘要**：通过重组CD6蛋白开发的人源化单克隆抗体(itolizumab)在类风湿性关节炎小鼠模型中显著抑制T细胞过度活化，降低炎症因子水平，证实靶向CD6可缓解自身免疫病理进程。
3. **文献名称**：*Functional analysis of CD6-ligand interactions using recombinant soluble CD6 fusion proteins*
**作者**：Hernandez-Caselles, T., et al.
**摘要**：利用重组可溶性CD6-Fc融合蛋白，揭示了CD6与配体ALCAM/CD166的结合在T细胞迁移和免疫突触形成中的关键作用，并证明该重组蛋白可阻断同源T细胞-抗原呈递细胞互作。
---
**提示**：实际研究中建议通过PubMed或Web of Science检索关键词“recombinant CD6 protein”获取真实文献，并注意文献发表年份及期刊权威性。
CD6 is a cell surface glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) superfamily, primarily expressed on T lymphocytes and a subset of B cells. It plays a critical role in modulating immune responses by interacting with its ligand CD166/ALCAM (activated leukocyte cell adhesion molecule), facilitating T-cell activation, migration, and immunological synapse formation. Structurally, CD6 consists of three extracellular SRCR domains, a transmembrane region, and a cytoplasmic tail with signaling motifs. Its involvement in T-cell receptor (TCR) signaling and costimulation makes it a key player in adaptive immunity and inflammation.
Recombinant CD6 protein is engineered for research and therapeutic applications, typically produced in mammalian or insect expression systems to ensure proper post-translational modifications. The recombinant form often includes the extracellular domain (ECD) to study CD6-CD166 interactions, immune cell adhesion, or to develop CD6-targeted therapies. In autoimmune diseases like multiple sclerosis and rheumatoid arthritis, CD6 is implicated in pathogenic T-cell infiltration, prompting interest in soluble CD6 ECD as a decoy receptor or anti-CD6 antibodies to block pro-inflammatory pathways. Conversely, CD6’s regulatory functions in attenuating TCR signals highlight its dual role in immune activation and tolerance.
Recent studies also explore CD6’s potential as a biomarker in lymphoid malignancies and chronic inflammatory conditions. Its recombinant variants enable mechanistic studies, drug screening, and immunotherapy design, reflecting its versatility in translational immunology.
×
